Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study by Jeanneret-Sozzi, Wendy et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Primary breast lymphoma: Patient profile, outcome and prognostic 
factors. A multicentre Rare Cancer Network study
Wendy Jeanneret-Sozzi1, Alphonse Taghian2, Ron Epelbaum3, 
Philip Poortmans4, Daniel Zwahlen5, Beat Amsler6, Sylviane Villette7, 
Yazid Belkacémi7,8, Tan Nguyen9, Pierre Scalliet10, Philippe Maingon11, 
Cristina Gutiérrez12, Pauline Gastelblum13, Marco Krengli14, Rita Abi Raad2, 
Mahmut Ozsahin1 and René-Olivier Mirimanoff*1
Address: 1Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon, CH-1011 Lausanne, Switzerland, 2Massachusetts 
General Hospital, 32 Fruit Street, Boston, MA 02114, USA, 3Rambam Medical Centre, PO Box 9602, Haifa 31096, Israel, 4Dr. Bernard Verbeeten 
Instituut, Brugstraat, NL-5000 LA Tilburg, The Netherlands, 5Universitätsspital, Rämistrasse 100, CH-8091 Zürich, Switzerland, 
6Universitätskliniken, Petersgraben 4, CH-4031 Basel, Switzerland, 7Centre Oscar Lambret, 3 rue F. Combémale, F-59000 Lille, France, 8Hôpital 
Tenon, 4 Rue Chine, F-75020 Paris, France, 9Centre Jean Godinot, BP 171, F-51100 Reims, France, 10Cliniques Universitaires St. Luc, Ave. 
Hippocrate Brussels, Belgium, 11Centre Georges François Leclerc, Rue du Professeur Marion, F-21034 Dijon, France, 12Institut Català d'Oncologia, 
Av. Gran Via s/n km.2.7, E-08907 L'Hospitalet, Barcelona, Spain, 13Institut Jules Bordet, 1 rue Héger Bordet, B-1000 Brussels, Belgium and 
14Ospedale Maggiore della Carità, Università del Piemonte Orientale, I-28100 Novara, Italy
Email: Wendy Jeanneret-Sozzi - wendy.jeanneret@chuv.ch; Alphonse Taghian - ataghian@partners.org; 
Ron Epelbaum - epelbaum@rambam.health.gov.il; Philip Poortmans - poortmans.ph@bvi.nl; Daniel Zwahlen - daniel.zwahlen@usz.ch; 
Beat Amsler - beat.amsler@aerztehaus-allschwil.ch; Sylviane Villette - y-belkacemi@o-lambret.fr; Yazid Belkacémi - y-belkacemi@o-lambret.fr; 
Tan Nguyen - tandat.nguyen@reims.fnclcc.fr; Pierre Scalliet - scalliet@rbnt.ucl.ac.be; Philippe Maingon - pmaingon@dijon.fnclcc.fr; 
Cristina Gutiérrez - svilla@iconcologia.net; Pauline Gastelblum - paul.vanhoutte@bordet.be; Marco Krengli - krengli@tera.it; 
Rita Abi Raad - ataghian@partners.org; Mahmut Ozsahin - esat-mahmut.ozsahin@chuv.ch; René-Olivier Mirimanoff* - rene-
olivier.mirimanoff@chuv.ch
* Corresponding author    
Abstract
Background:  To asses the clinical profile, treatment outcome and prognostic factors in primary breast
lymphoma (PBL).
Methods: Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare
Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an
unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received
radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12–55 Gy).
Results: Ten (12%) patients progressed locally and 43 (55%) had a systemic relapse. Central nervous system
(CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free
survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable
prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment.
Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors.
Conclusion: The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but
systemic relapses, including that in the CNS, occurs frequently.
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Background
The term "primary breast lymphoma" (PBL) is used to
define malignant lymphoma primarily occurring in the
breast in the absence of previously detected lymphoma
localizations.
The breast is a rare site for non-Hodgkin's lymphoma
(NHL) and represents only between 0.38 and 0.7% of all
NHL, and between 1.7 and 2.2 of all extranodal NHL [1-
5], accounting for only 0.04 to 0.5% of all breast malig-
nancies [2,3,5-10]. With the exception of the recently pub-
lished prospective Mexican trial which included 96
patients with PBL [11] and the large study of the Interna-
tional Extranodal Lymphoma Study Group (IELSG) [12],
we were able to find in the literature only retrospective
studies with a relatively limited number of patients, often
mixed with cases of secondary breast involvement, single
case reports and clinicopathologic studies, the latter often
lacking any follow-up information.
So far, the largest retrospective series with genuine PBL
and sufficient follow-up identified 204 patients from the
IELSG [12]. Other studies included between 20 and 53
cases and provide some interesting information [3,6,13-
20]. However, because of the limited number of patients
and the sometimes extended time span, the parameters of
this disease, such as natural history, prognostic factors,
impact of treatment, patterns of failure and survival have
not been always well identified. For this reason and to col-
lect a larger number of patients affected by this rare entity,
we have performed a multicenter international retrospec-
tive analysis on PBL within the Rare Cancer Network [21].
The purpose of this study was to better assess the clinical
profile, treatment parameters, patterns of failure, survival,
and prognostic factors in patients presenting with PBL.
This report includes 84 patients with PBL.
Methods
Patient characteristics
Eighty-four patients with primary breast lymphoma (PBL)
were evaluated and treated in 20 member institutions of
the Rare Cancer Network between 1970 and 2000. By def-
inition, all cases presented with a lymphomatous involve-
ment of the breast as the first manifestation of their
disease with no previous diagnosis of NHL of any type or
site.
The 84 patients included 83 women (99%) and 1 man.
The median age was 64 years (range 28–90 years). The
median follow-up was 56 months (range 9–188 months).
Five patients presented with a previous cancer in the fol-
lowing sites: uterus (2), tonsil (1), kidney (1), bladder (1),
and 2 had a concomitant cancer: of the breast (1) and soft
tissue sarcoma of the leg (1). All were pathology-con-
firmed NHL, 46 with stage IE, 33 with stage IIE, 1 with
stage IIIE and 2 with stage IVE, according to the Ann Arbor
classification [22]. For 2 patients, the stage could not be
retrieved. All patients received treatment with curative
intent. The pathology reports were centrally reviewed. All
NHL in this series were classified or reclassified according
to the Working Formulation [23] as it was thought to be
the most reproducible classification when reclassifying
cases which were included in this 30-year period and com-
ing from 20 different institutions. Thus, 51 patients
(61%) had a high-grade, 6 (7%) an intermediate grade,
and 27 (32%) a low-grade NHL.
For all patients, data on the medical history and physical
examination were available. In fifty-one patients the ini-
tial sign was a palpable mass, in 9 there were local inflam-
matory signs, 10 had pain, 21 had palpable lymph nodes,
and in 10 patients the PBL was discovered by a routine
mammography. Staging work-up for all patients is shown
in detail in Table 1, while patient characteristics are sum-
marized in Table 2.
Surgery
Surgery consisted of mastectomy with (16) or without (5)
axillary dissection, quadrantectomy alone (3), tumorec-
tomy with (1) or without (35) axillary dissection, and
biopsy alone (23). In one case, the type of surgery could
not be identified. The majority of patients received post-
operative treatment: 37 radiotherapy combined with
chemotherapy, 22 chemotherapy only, 14 radiotherapy
only, whereas 11 patients had no treatment after surgery.
The reasons for not giving any adjuvant treatment were
patients' refusal and age in 2. For the remainder, the rea-
sons could not be retrospectively identified.
Radiotherapy (RT)
Amongst the 51 patients (61%) receiving radiotherapy, 41
were treated on the whole breast, 7 on the thoracic wall,
and 27 on the regional lymph nodes with or without
breast/chest wall irradiation. The median RT dose was 40
Gy (range 12–55 Gy) at a median daily dose of 2 Gy
(range 1.8–3 Gy). Except for 1 patient treated with elec-
trons on the thoracic wall, all breasts or thoracic walls
were treated with tangential photon fields.
Chemotherapy
Fifty-nine of the 84 patients (70%) were treated with
chemotherapy. For 25 of them, chemotherapy consisted
of CHOP (i.e. cyclophosphamide, doxorubicin, vincrins-
tine and prednisone). Ten patients received a CHOP-like
regimen (i.e. cyclophosphamide, epirubicin, vincristine
and prednisone), 11 CHOP plus bleomycine and 2 CHOP
plus methotrexate. Three patients received a CVP regimen
(cyclophosphamide, vincristine and prednisone) and 3
chlorambucil alone. Five patients received other chemo-
therapy drugs, including various combinations of cyclo-BMC Cancer 2008, 8:86 http://www.biomedcentral.com/1471-2407/8/86
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phosphamide, mitoxantrone, VM-26, doxorubicin, and
prednisone. The median number of chemotherapy cycles
was 4 (range 1–12). Only one patient received one cycle
and 2 patients 2 cycles. This was due to haematological
toxicity 2 or non-haematological toxicity 1.
Statistical Analysis
Overall survival (OS), lymphoma-specific survival (LSS),
disease-free survival (DFS), and local control (LC) were
calculated from the day of histology examination using
the Kaplan-Meier method (243). The events were death
(including all causes of death) for OS, death or relapse for
DFS, death from lymphoma for LSS and local relapse for
local control. Differences between groups were assessed
using the log-rank test [25]. We screened for independent
prognostic factors with a Cox regression analysis [26]. A p-
value of < 0.05 was considered statistically significant.
Results
Local and systemic relapse
Following treatment, 10 of the 84 patients (12%) pre-
sented with a local relapse. The median time to local
relapse was 17 months (range 2–61 months).
Systemic lymphoma relapse, with or without local
relapse, was observed in 43 of 84 patients (55%). The sites
of the first systemic relapses were deep-seated (thoracic
and abdominal) lymph nodes (n = 13), peripheral lymph
nodes (n = 8), central nervous system (CNS) (n = 12),
bone marrow (n = 7), pleura (n = 5), skin (n = 4), lungs
(n = 3), spleen, muscles, orbit, stomach, Waldeyer's ring
and kidney (each n = 2) and liver (n = 1). Of the 12
patients with CNS relapse, 10 or 85% had a high grade
lymphoma, versus 61% for the entire group of patients.
The median time to systemic relapse was 22 months
(range 4–140).
Survival
The 5-yr OS, LSS, DFS and LC were 53%, 59%, 49%, and
87% respectively (Fig. 1). Thirty-four patients died due to
PBL and 8 due to other causes (1 from metastatic lung
cancer, 1 from septicemia, 1 from small bowel obstruc-
tion, 1 from liver insufficiency, and for 4 patients the
cause of death could not be retrieved).
Prognostic factors
Univariate analyses revealed that early (IE) stage was a sta-
tistically significant favorable prognostic factor for OS,
LSS, DFS and LC. Mastectomy was an adverse factor for OS
and LSS, whereas RT was a statistically significant favora-
ble prognostic factor for LSS and LC. Chemotherapy only
marginally improved the LC but without reaching a signif-
icant level. Combined modality had only a positive and
significant effect on local control (Table 3).
Table 1: Staging work-up in 84 patients with primary breast 
lymphoma
Staging work up n %
Mammography 65 77
Mammary ultra sound 25 30
Mammary MRI 7 8
Chest x-ray 72 86
Chest CT-scan 66 79
Abdominal CT-scan 70 83
Abdominal ultra sound 28 33
Bone marrow biopsy or aspiration 77 92
Lymphography 11 13
Bone scintigraphy 17 20
CSF examination 14 17
CBC 82 98
ESR 67 80
Serum protein electrophoresis 52 62
B2 microglobulin 39 46
MRI: magnetic resonance imaging
CSF: cerebrospinal fluid
CBC: complete blood count
ESR: erythrocyte sedimentation rate.
Table 2: Patient characteristics
Characteristic N %
Gender
- male 1 1
- female 83 99
Symptoms and signs
- local pain 10 12
- local inflammation 9 11
- palpable mass 51 61
- palpable lymph nodes 21 25
- incidental mammography finding 10 12
Localization (71 patients)
- external superior 34 48
- internal superior 10 14
- external inferior 9 13
- internal inferior 5 7
- central 12 17
- entire breast 1 1
Tumor size (71 patients)
- 0 – 1.9 cm 4 6
- 2 – 4.9 cm 35 49
- 5 – 9.9 cm 23 32
- 10 – 15 cm 9 13
Stage (82 patients)
- I E 46 55
- II E 33 39
- III E 1 1
- IV E 2 2
- unknown 2 2
Grade (according to Working Formulation)
- high 51 61
- intermediate 6 7
- low 27 32BMC Cancer 2008, 8:86 http://www.biomedcentral.com/1471-2407/8/86
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In multivariate analysis, early stage was a significant favo-
rable prognostic factor for OS, LSS, DFS, and LC (p values:
0.002, 0.001, 0.04, 0.03, respectively). Tumor size of
more than 4 cm was an adverse prognostic factor for OS
and LSS (p values: 0.01 and 0.007 respectively). RT was a
favorable factor for local control (p = 0.02).
Side effects of RT
Sixteen patients were reported to have grade 1–2 skin reac-
tions, 2 presented with grade 2 esophagitis, and 2 with
local edema. Only 1 patient developed grade III toxicity,
consisting of radiation-induced pulmonary toxicity.
Discussion
To our knowledge, our series of patients collected in 20
institutions of the Rare Cancer Network is the second larg-
est retrospective analysis of PBL, with 84 patients treated
over a 30 year period. We have identified one recent pro-
spective trial from Mexico with a larger number of cases,
including 96 patients with PBL [11] and the large series of
the IELSG with 204 patients [12]. Other studies with more
than 20 patients with PBL were reported by investigators
from the MSKCC (53 cases), Japan (48 cases), City of
Hope (41 cases), Stanford (37 cases), Harvard (32 cases),
The Mayo Clinics (26 cases), The Netherlands (25 cases),
MDACC (23 cases), France (22 cases), and Institut Gus-
tave Roussy (20 cases) [3,6,13-20]. Some of these reports
have also included secondary breast lymphoma
[3,6,14,15] and in one of them no information on follow-
up was provided [3].
Overall survival (OS), lymphoma-specific survival (LSS), dis- ease-free survival (DFS) and local control (LC) in 84 patients  with primary breast lymphoma Figure 1
Overall survival (OS), lymphoma-specific survival 
(LSS), disease-free survival (DFS) and local control 
(LC) in 84 patients with primary breast lymphoma.
Table 3: Univariate analysis (logrank test)
n 5 y OS (%) P value 5 yr LSS (%) P value 5 y DFS (%) P value 5 yr LC (%) P value
All patients 84 53 59 41 87
Age (yrs)
• <64 42 60 0.07 67 NS 45 NS 92 NS
• >64 42 44 49 38 82
Stage
• I E 46 62 0.007 70 0.006 52 0.05 92 0.05
• II E 33 40 44 28 81
Grade
• High 51 42 NS 50 NS 36 NS 85 NS
• Low/intermediate 33 66 70 48 90
Tumor size
• < 4 cm 38 58 NS 68 NS 40 NS 91 NS
• > 4 cm 33 43 44 43 83
Surgery
• C.S. 63 62 0.03 69 0.01 48 NS 91 NS
• Mastectomy 21 22 26 18 78
RT
• Yes 51 58 NS 70 0.02 41 NS 95 0.005
• No 33 46 46 40 76
Chemotherapy
• Yes 59 47 NS 51 NS 39 NS 92 NS
• No 25 61 72 44 77
Combined modality
• Yes 37 54 NS 64 NS 37 NS 96 0.03
• no 47 51 56 43 81BMC Cancer 2008, 8:86 http://www.biomedcentral.com/1471-2407/8/86
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Patient characteristics and pathology
In our study, the median age was 64 years, which is com-
parable to the 60–65 year range published by other
authors [11-16]. Aggressive PBL has sometimes been asso-
ciated with younger age [5,14]. PBL is extremely rare in
males, with only one of our 84 patients, 1 of 23 patients
from MDACC, 1 of 25 from the Mayo Clinic, 1 of 18 from
St. Cloud [16,17,27], and none in the other series [11,13-
15].
In the present experience, the most prominent initial signs
were a tumor mass, a mass with local inflammation, and
palpable lymph nodes. In the other series, a painless mass
was the most commonly presenting sign in 80–100% of
cases [13,16,28]. Ten of our patients (12%) were diag-
nosed by a routine mammography, which is higher than
in other series [14]. A second preceding (n = 5) or syn-
chronous (n = 2) cancer was present in 7 (8%) of our
patients whereas in the MSKCC series, 17% of patients
presented with a second cancer [13].
According to the Working Formulation, 61% of our
patients had a high-grade, 7% an intermediate grade, and
32% a low-grade PBL. A predominance of diffuse large cell
PBL was a constant feature in the IELSG, the Dutch, the
MSKCC, the MDACC and the City of Hope pathology
reviews, whereas the proportion of low or intermediate
grade PBL was variable [3,12,13,15,16]. According to the
comprehensive literature review by Brogi and Harris, the
majority of PBL are diffuse large B-cell lymphoma (40 –
70%), MALT-type has a reported incidence of 0 – 44%,
whereas the rare Burkitt's NHL can bilaterally involve the
breasts of young, pregnant or lactating women with very
aggressive clinical behavior [5].
Diagnostic workup
For all patients, a medical history and physical examina-
tion were carried out. Seventy-seven percent of our
patients underwent a mammography, 30% breast US and
8% breast MRI. Of interest, only 85% of the mammo-
grams and 72% of the ultrasound examinations were
interpreted as abnormal. In contrast to this, in the Har-
vard series, mammograms done after physical detection of




Strikingly, mastectomy was associated with a poorer sur-
vival in the univariate analysis, compared with conserva-
tive procedures or biopsy. A higher risk of failures with
radical surgery was also noted in Fruchart et al's report
[18] and an adverse effect on cancer-specific survival was
seen in the IELSG series [12]. Although the adverse effect
of mastectomy can be influenced by other confounding
factors, radical surgery is at best unnecessary and should
be avoided in PBL. Ideally surgery should be limited to a
biopsy to establish the correct histological diagnosis, leav-
ing the treatment with curative intent to radiotherapy and
chemotherapy [11-13,18,19,29].
Radiation Therapy
Fifty-one (61%) of our patients received radiotherapy,
with or without chemotherapy. The median radiotherapy
dose was 40 Gy (range 12–55 Gy) at a median daily dose
of 2 Gy. No dose effect relationship could be found. In
addition, we were not able to demonstrate an impact of
elective nodal irradiation. The majority (8 of 10) of the
patients with a local relapse, did not receive post-opera-
tive radiotherapy. Thus, radiotherapy to the breast or to
the thoracic wall had a statistically significant positive
impact on local control, with 95% vs. 76% 5-yr local con-
trol rate (p = 0.02). In their series of 19 patients treated
with definitive RT at MSKCC, De Blasio et al. found a local
control rate of 78% [26]. The positive role of radiotherapy
was also suggested in other series [12,20,28,30]. These
and our results confirm the central role of radiotherapy in
PBL.
Chemotherapy
Chemotherapy was associated with a non-significant
trend towards a better local control rate, (92% vs. 77% at
5 yrs). No effect could be demonstrated on overall or lym-
phoma-specific survival. In most reports, patients with
intermediate or high grade PBL have received adjuvant
chemotherapy [12,14,16,19,27,28,30-34]. Because of the
high proportion of patients receiving chemotherapy in
these series, it is difficult to define its precise role,
although a positive impact on local control [30] and
relapse [15] is suggested. In the IELSG series, anthracyclin-
based chemotherapy was associated with higher overall
survival [12]. In low-grade lymphoma, the role of adju-
vant chemotherapy is very doubtful.
In addition to these various systemic treatments, newer
therapies, such as rituximab [35,36] deserve further inves-
tigation, but experience in PBL is still limited [37].
Combined modality treatment
Thirty-seven (44%) of our patients were treated with com-
bined modality treatment. A favorable impact on local
control was observed (p = 0.03) in the univariate analysis
which was not confirmed in the multivariate analysis.
Aviles et al have recently published their randomized trial
of PBL in which 96 patients were allocated to radiotherapy
(n = 30), chemotherapy (n = 32), and combined modality
treatment (n = 34) [11]. All were staged IE or IIE PBL, with
a good balance of prognostic factors between the 3 treat-
ment groups. At 10 years, actuarial overall survival was
50%, 50% and 76% (p < 0.01) respectively [11]. A posi-BMC Cancer 2008, 8:86 http://www.biomedcentral.com/1471-2407/8/86
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tive impact of combined modality in PBL is also suggested
is several retrospective series [12,15-17,19,33].
Overall prognosis
With regard to the outcome of patients with PBL, overall
prognosis was only fair, with an overall 5 yr survival rate
of 53%. Even for stage IE, 5-yr overall survival was only
62%. The 5-year survival reported in other series varied
from 50 – 82% [11,12,16,17,20,30,33] and was likely to
be related to the distribution of prognostic factors in the
different series.
Local control
The local control rate in our series was 87% at 5 years.
Unfortunately, information on local control in most other
series is vary scarce. DeBlasio et al report a 78% local con-
trol rate [29] and in Dao et al's series only 1 of 13 patients
presented with a local relapse [30] whereas in Ganjoo's
series no recurrence occurred in the involved breast [20].
In spite of these limited data, overall local control for
patients receiving RT alone or combined with chemother-
apy appears to be generally excellent.
Systemic relapse
Forty-three patients (55%) suffered from a systemic
relapse predominantly in deep-seated (n = 13), and
peripheral (n = 8) lymph nodes, the central nervous sys-
tem (n = 12), and bone marrow (n = 7), after a median fol-
low-up of 22 months (range 4–140 months). The high
rate of central nervous system relapses in PBL was also
found in other studies [11,17,19,34], and some authors
have raised the question of prophylactic central nervous
system therapy [11,12,19,34].
Prognostic factors
As shown in other studies of the Rare Cancer Network, the
successful collection of data for rare cancers enabled us to
define various prognostic factors. In univariate analyses,
there was a borderline non-significant trend for a better 5-
year survival in patients younger than 64 years. Stage IE
was highly significantly better than stage IIE concerning
overall, lymphoma-specific, disease-free survival, and
local control. Concerning treatment, surgery had a statis-
tically significant negative impact on overall and lym-
phoma-specific survival, and radiotherapy a statistically
significant positive effect on lymphoma-specific survival
and local control. Neither chemotherapy nor combined
modality treatment significantly influenced OS, LSS, and
DFS, whereas combined modality had a significant
impact on local control.
In the multivariate analyses, early stage remained statisti-
cally significant for OS, LSS, DFS and LC, tumour size for
OS and LSS, whereas RT was significant only for LC. Prog-
nostic factors were also found in some of the other stud-
ies. In particular, Ann Arbor Stage [13,16,17],
International Prognostic Index [12,16], and grade [13]
had a positive impact on overall survival and disease-free
survival.
Conclusion
Primary breast lymphoma is a rare presentation of NHL.
Therefore one should remain cautious in drawing strong
conclusions. However, as we have analyzed one of the
largest groups of patients with PBL, we can conclude that
overall prognosis is only fair, that local control is excellent
with RT or combined modality treatment but systemic
relapses, including in the CNS, still occur frequently. The
identification of several prognostic factors may be useful
indicators regarding the overall management of PBL.
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